AMWL vs. AUGX, NUTX, MPLN, IMAB, RENB, RPTX, ELMD, CTMX, CYBN, and SCPH
Should you be buying American Well stock or one of its competitors? The main competitors of American Well include Augmedix (AUGX), Nutex Health (NUTX), MultiPlan (MPLN), I-Mab (IMAB), Renovaro (RENB), Repare Therapeutics (RPTX), Electromed (ELMD), CytomX Therapeutics (CTMX), Cybin (CYBN), and scPharmaceuticals (SCPH). These companies are all part of the "medical" sector.
Augmedix (NASDAQ:AUGX) and American Well (NYSE:AMWL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
Augmedix has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, American Well has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
American Well received 28 more outperform votes than Augmedix when rated by MarketBeat users. However, 50.00% of users gave Augmedix an outperform vote while only 47.06% of users gave American Well an outperform vote.
Augmedix has a net margin of -41.95% compared to Augmedix's net margin of -137.32%. Augmedix's return on equity of -46.76% beat American Well's return on equity.
Augmedix presently has a consensus price target of $3.88, suggesting a potential upside of 252.14%. American Well has a consensus price target of $0.80, suggesting a potential upside of 84.59%. Given American Well's stronger consensus rating and higher possible upside, equities analysts plainly believe Augmedix is more favorable than American Well.
In the previous week, American Well had 1 more articles in the media than Augmedix. MarketBeat recorded 4 mentions for American Well and 3 mentions for Augmedix. American Well's average media sentiment score of 1.25 beat Augmedix's score of -0.31 indicating that Augmedix is being referred to more favorably in the media.
Augmedix has higher earnings, but lower revenue than American Well. Augmedix is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.
87.1% of Augmedix shares are held by institutional investors. Comparatively, 56.1% of American Well shares are held by institutional investors. 11.0% of Augmedix shares are held by insiders. Comparatively, 12.8% of American Well shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Augmedix beats American Well on 10 of the 18 factors compared between the two stocks.
Get American Well News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMWL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
American Well Competitors List
Related Companies and Tools
